N
Google TrendGME (1000+) — GameStop Stock Hits a New 52-Week High: What's Going On?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:gme1000+pope francis200+nicolò tresoldi500+michael olise1000+bank of america fine1000+club brugge500+rb leipzig200+saudi news1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "FDA clears first daily pi" (30 stories)

Top Headline Story

FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)
Lead StoryMerck | Hometech
Apr 21

FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQUU9lLS1OUlk3RXVjbXdCWHV3ZGUweUpfdlJEVkJ3Ump1U3llWEt2cDNyYmhaam5iMFJnVmZZUWdqTFF1YzVTdUJBbHhOalpXQlNnLVpka053VVQxN0Z6SlZqbktCbFg2N2E2YlhCajBrZmxNLURyajFVd2lVcDVTWTZxZ2NrZlpnS3lCMVF0VWk2Zw?oc=5" target="_blank">FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)</a>  <font color="#6f6f6f">Merck | Home</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+21m ago

gme

GameStop Stock Hits a New 52-Week High: What's Going On?

Filter stories
200+21m ago

pope francis

The Myth of St. Francis

Filter stories
500+31m ago

nicolò tresoldi

Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League

Filter stories
1000+31m ago

michael olise

The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu

Filter stories

Search Results for "FDA clears first daily pi"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
PR Newswiregeneral

FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUURwUGpweFJXZ09DbTJBSUV1azYxVTdYWWppUEFUaGRVOVRIUXZENXlrTkFKOTBlc2tkRnlKeXgwSll2REdlQjJQbEtWMGFZRDY5TENENWhNWjB5R2RrRlFsQlA3bzVjSlJsQXYwR3ktSjNVTFdOMjB4dGRzQ2Vyd1RtQi1UN2JLNHlTZGprV01wQVNJakFMTV9YZHo1aEF5TkpwQmV0c2NaM2Y3c0x4bzhobW9ENTdrdjBOS291MDdpcmc?oc=5" target="_blank">FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
Yahoo Financegeneral

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNYWw2V0ZJbzZBZl85a21wUHNzQk94Y0JaR2FBRnN4Y1B0NFE0ZDh0MG1BUkh0MVgzc3gzX2UwVkp4UEE4Z3E0REFrYzgxdTh4bUhRNkxha2ktRnZKUW5RY3p2ZVdrSUhZS2k4aE5MbTVOUXk5cUVUVHUweTJfNjUzMUpGRWY1cDBJMjc5dXlhNzNPRUwxN2dvUXduaUo?oc=5" target="_blank">FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients
Pharmacy Timesgeneral

FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOS21hQldka2NqeVcwZEVfdnRHbXB4U2VlcHVkakYxRnFMU2VJaktEOXNuMzl6NGgxN280UHRGSHowa2RFczN5S2ZHS3Bic0RZS2lWTEdYRmxCMjBrOXo3V2dtbTZZQ1FWZGk1bGZLazhvNjVoY2VRcTNqYkpyS0dHdjBLaGd2eDYwaEI4bldZMTVWZGtBTm92OWlmQ2tDZWtqcHhSd1BFb21rMm1nT0NOaWVYT0VxS18ydFE?oc=5" target="_blank">FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Eli Lillyworld

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOay1xOERpNzdtOUpGbklyMHNtRnkyaDNxTVJRcHFwUVBmRFN2UjRsV3B4OGRzdlYzdjNvdVpEYTFselBRYmFkSVZUUUFGT0MzQVNjQUJtT3dlbjRvcmN0YW54SDJ0YmtaUDFkdTBKM0FTN1FKc3h5RWEweTRVWVVNd0diSWdkZkJRWW1HTTk5RVBpMVRuQm5HV2pvcl84VWxrWGhfaHlOLUVlcGx6UmVuTWxUZk15WWRRZXlocmR3?oc=5" target="_blank">FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions</a>  <font color="#6f6f6f">Eli Lilly</font>

Read Full StoryMore like this
Simtriyo Gains FDA Approval as First NDSRI CNS Stimulant for ADHD
Neurology Advisortech

Simtriyo Gains FDA Approval as First NDSRI CNS Stimulant for ADHD

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxPbkJfTXY1Q0ROZXBERC11QTVZeEVrbGZnOUN6SlJkUG9la3dyd1dhZHJlVlV6OFlXRU85anh0VldCbTBOSkwwQlhDS3NUbUlKbEdhZVdKSnltT0xTUlBwQTFqMHZHMnlUdHMxRjlhQjMwam9ZbWo2T1JuSEhGTkl0eGZUN3Zfdw?oc=5" target="_blank">Simtriyo Gains FDA Approval as First NDSRI CNS Stimulant for ADHD</a>  <font color="#6f6f6f">Neurology Advisor</font>

Read Full StoryMore like this
FDA Approves Enlicitide, an Oral PCSK9 Inhibitor, for LDL-Lowering
TCTMD.comgeneral

FDA Approves Enlicitide, an Oral PCSK9 Inhibitor, for LDL-Lowering

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQd1VQZEQ4WkdGdUcyaXV5dXBHZk5WdnVXbWM0STltWVpkNTVkdm9YMVZIWVRqdFNTQms3am5NMENZUVFOaWZTX3hiSG5DM2JsRGxlWlBMckJZX3VaeUVYeWIzSTJPOGpCZHhDOHdPcGZib2Utdk82MTVkSGVkQzB2LWx0bW84NVpHSnozNw?oc=5" target="_blank">FDA Approves Enlicitide, an Oral PCSK9 Inhibitor, for LDL-Lowering</a>  <font color="#6f6f6f">TCTMD.com</font>

Read Full StoryMore like this
FDA Approves First Once-Weekly Insulin for Type 2 Diabetes
Medscapegeneral

FDA Approves First Once-Weekly Insulin for Type 2 Diabetes

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQWXROVEVUMWNDTHFWMjZNS1BoV282SEgtVzYyNERUV0dWd2dSbGVrTklCdy1wT1dOeEhjdUNfWGtGMjM1SVh2YWhfOXZ0bUdnb1htbEFxVnpsdDEyRnV5OHVRUXAwZ3FBRVdMWGpzOEx4aEliREYwT1pWVnZmZkhzNEl5aFJLRHBjeVlqY1RER2NFRF9fTVRfaUNVVnU4Y2NiWkE3cFlpZw?oc=5" target="_blank">FDA Approves First Once-Weekly Insulin for Type 2 Diabetes</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
The American Journal of Managed Caregeneral

FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPdDVsRncyNDJIWU42X1AzblQyZVh3bEJzeUlfUUU1VXFiM0Nabk1ZUXBCS1hkS0Z5V3paRm1xUHdVeTc4UzlmTkZGTEFubmw5SVozTHpHT3E0eWdYQlFVcWJ1d1lGZnF2dGxPV3ZtMHE4WC14NU41a2lrS2lEdG1pdFlhdHVTanJzeVlBajl2T1JRbWhBdnc?oc=5" target="_blank">FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
FDA approves Tenpoint's YUVEZZI as first dual-agent presbyopia drop
Glance by Eyes On Eyecaregeneral

FDA approves Tenpoint's YUVEZZI as first dual-agent presbyopia drop

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOeXFVcDB1V2xPcnh6ZXRCejQwTWM5ek1kb05yZGpyZmJsWTFJSFFJa2dBWEhVZmR3MEZ2cjRWc1hadHBBTzdldjFRVExyU01wSDI0ZzhObjVXQnBBYVpQazJmbTdRRTI4d0p0NkxJcFM1MWl2WmxOTlg3QUE2eFA5MHhRTjdOUHR5aVlaVlFWcUFuU19jQVh0Z1ZFNVcxWElCdnBqYkNFa2tWRlp5elFLOUM3MlFVNHk2cWk1Uw?oc=5" target="_blank">FDA approves Tenpoint's YUVEZZI as first dual-agent presbyopia drop</a>  <font color="#6f6f6f">Glance by Eyes On Eyecare</font>

Read Full StoryMore like this
FDA approves Wegovy pill for weight loss: What to know - ABC News
Breaking News, Latest News and Videosgeneral

FDA approves Wegovy pill for weight loss: What to know - ABC News

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPUktKS1pLZHAtam5tT0kydmtRY0dLRmx6ZUFYdURtRVFxODZmdURraHVOb0d6OTgtaDJ2VEZFX1BwMWJkSVRncTVsQWxMNHQ1YWY2WEVBVHpsYm5oemJzMzQ4TzhFd19OQUpUUXgzeVlkTUtjZV9jME9oejZVSlFhZlRPM3VaNVJZa3dEdUVMdXFNUdIBlwFBVV95cUxPWjNsZjF4eHdJUUJEcW80T0UxNWVJNlUwaXc0ai1QUDJiak5Xek00bFlUNmZYdTFnTU1oWGw3VDF2emd0S3lmOE1xY3owYzgzSnUyRnRTRy1uZlZPUnBtUmppY3Nnb21FRHFLOUtDTFVta3RuR1lSejZpd1Z3QkxKMWhCcXp5YVJuOWd0OGFkb05LYW5PLTlZ?oc=5" target="_blank">FDA approves Wegovy pill for weight loss: What to know</a>  <font color="#6f6f6f">ABC News - Breaking News, Latest News and Videos</font>

Read Full StoryMore like this
FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs
Drug Topicsgeneral

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQdTJqOFdTeVozWDNRUlBlVy1WRHF1TDE5djlvcmRkUVVrTEhSWnQ1MWRyamNnT3FJZDhBNlRCNXc0OVJKcW9oOXpiVFp0ZHN1UHE3OTBjQlZhZTFWUWVEWUJ1WXBYbUVHZnVGaUpCZVpQODRrYks1MlI3U0Y0SlhpNlRfRHVkSzBQeWtlTHI4bU5IemFFeGxEcjhzcXdBdw?oc=5" target="_blank">FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs</a>  <font color="#6f6f6f">Drug Topics</font>

Read Full StoryMore like this
FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications
PR Newswiregeneral

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxNMGhOMEVEU0l6bjh6V3pDNFB0MDhfR3ZLM24xX3FwY0t6Yi1rY3R5UF9sWkRwVDU1Z05vU2ZmeWp3djBiRlZKMWg3TUJTUmxTaHpQaWNWdEtiNTFsTTRPam8ta1E4c3dxajdDT2trV0N3Q1BrbTlpd0dLQUtCLVdaYmd0aFlINjJJOV80ZksyZFRIeXRMXzNwYVNvWkRGUnJLVkc3X2NLNlprTnVMSXJYTkxQTmdVVUphT240SkZtS0N6dUk0N29KTUxMRlpLNm5lYVMyXzVneHJyQnpWdW1xYjNPZnBLNGRQWUthTndxZ1lhSmdtc3I2YzByMkR0Yk5fbGJxVWp4S3NEdDU5dkNHV25vU0ROaEhjM1cwVi13OA?oc=5" target="_blank">FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
FDA Approves Icotrokinra, First Oral IL-23 Inhibitor for Plaque Psoriasis
The American Journal of Managed Caregeneral

FDA Approves Icotrokinra, First Oral IL-23 Inhibitor for Plaque Psoriasis

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPU0Zqc1hleDlxTWM0cFMzVk1JTHE5V1B3S3pyNWRKX0g0QmF0cWppLWdBU25tQjZvVndxZDdhTkh5WnJ5aXhtc3NLQy14U0NFQ2d2THJPSnRWa1pPZGxBNUZSYndyTlhBTFFITkFDTUFPVlpja19RbzRhTXF3bWRyV2UyRWN1eXR1VnZMSWZLcXM3QzRFcUM3dklFYkZxVGc?oc=5" target="_blank">FDA Approves Icotrokinra, First Oral IL-23 Inhibitor for Plaque Psoriasis</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Biogentech

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQRDJ3S2FGX3daTm41ejhpZS1CRmtPemRUMGJBdE5mRFZFMDZjRzhKNHptWVRIRG9rc3JsbzkzbnFpZEVQYlJ2a09pNnBXYUVuZW5FcXE4TThQdmktR05adVRHeGVoZU02ZnU0R3FQRldVLTBIdGVQZUV3V3JTaTBnQ0R6MDlNY3IteDBqdXpkZ0JENzJjSTU0aXdHaWVXN1pNTkR4STgyR2piTk43NmVaNFkwMVNiWWNNWUpQWnBR?oc=5" target="_blank">FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
LENZ Therapeuticsworld

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNQ0tVa2pCR1BtbjhUcld6anVwN3pxMkhmOGQ4QVhYeXplSVF2Z1liR0NrYjhScDZ6bkdFSnE0d09uQS1kcEVBclR0bmN0cG95YnplZW5feEx4MVkzaUp5NUhzWUljOFJ1SDJVVkwwM1NuYWdaelc4dlZPajZJTlB1Sm5MSkhEbnloRUhRbllXcWpFdzVMcWUxNS1JRWxyNUNlMmNVcE5wcFI4YzAtNUY1UmpnMkYxcEVZeVozS0wzTXB4eFBhcU5TeWNLUXVUbWFXMm1INTg4UnJ0ZTQ?oc=5" target="_blank">LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia</a>  <font color="#6f6f6f">LENZ Therapeutics</font>

Read Full StoryMore like this
FDA Approves First-in-Class Drug for Generalized Myasthenia Gravis
Medscapegeneral

FDA Approves First-in-Class Drug for Generalized Myasthenia Gravis

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNY0pHeWRRNVdvMTRfZWhqaDB2SURvVzAzUmdia3lJMm9Fa0U5am1FSkhhTjItWl9iWklUNHNOMktWMmhMelpLTFZVOFhvVzNheU9zUkxmZEM5a1ROaXdwc2Q0WWs2c0pWQkM1dENVMV9qUGFuT2kwQWpZaFhqYWZ2LV9EbTFua2JPVkJEQ1RBT3czQl9aTXotRFdXdXRYTzhlMEJEdEFib2V3RjY1bGc?oc=5" target="_blank">FDA Approves First-in-Class Drug for Generalized Myasthenia Gravis</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
FDA Approves Zenbexus Combination for Patients With Multiple Myeloma After Prior Treatment
Cure Todaygeneral

FDA Approves Zenbexus Combination for Patients With Multiple Myeloma After Prior Treatment

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPUEVUQnZuS3lMQ1lUdjNrSTU1NkxOVVdISDZiY3ZHbmVUR1hXS0hDWmVISTh6YlVmOUUzazI3MWNaTEtKLUVhVUNnTExQVVNnN21xQjFQR3hGQ2hQWXhieUZGUXh3VmVXOUl4aHlpTmcxS3NlYnU5amhZM3N3SDJOTlR4MmZOZFp0OE0tUEU3NG8wdHo1MjUtOWlLN3NpZ0xKRXNtNkJrbUM1c3NrbktJRXUyWmFYMHcteFNZejh3?oc=5" target="_blank">FDA Approves Zenbexus Combination for Patients With Multiple Myeloma After Prior Treatment</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
FDA Approves 10% IVIG Formulation For Adults With Primary Humoral Immunodeficiency
Pharmacy Timesworld

FDA Approves 10% IVIG Formulation For Adults With Primary Humoral Immunodeficiency

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNYnE5b1p0eVRoQWNNVHdiNExDVG1kLXdRdVNuWFRUUHQ3enNUQUNpdzcyU1hjNTZfQmU3OTFTNjlocTVzNHFMNkgwZG14UDM5cTM0c2VsekpzWTk5SXRBY1MwZnJwUXdpQXdqTXQ2ZlEzRDdId2ZVSnlBNDR1dWdXZ3d1LXFyd2R4UDV4Nm1BbFdFbG5KcW1sM09nd3A0Q20zMnM1OURzRl81Zmgwb2tQN3d4ZXBaa1E?oc=5" target="_blank">FDA Approves 10% IVIG Formulation For Adults With Primary Humoral Immunodeficiency</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
PR Newswiregeneral

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

<a href="https://news.google.com/rss/articles/CBMirAJBVV95cUxNdlFfdXlZdUpuNGlkd0ZtOGlleXJlc0hkbW5XSjFTXzNETHlCSGQzb2EzQzg3NHpIUmQtX0pDM3ZrQzZFeE1zcHQtQkZIZTk3MGc5ZHlzenZZQTBBYW1BNkZHOG9jSFplM2JSYklGdzliVHdteS13Q2dRSjNBS2x2bWNWOTh0OTZkeE5DV3NOQ3htcE1yeFlkbHVUaUNTTmo0S2xNN2pMMHNXU0NiZWp2cXdvOHdTaElKZ1hmUHdtaFFaTi1TRk01bnlEUUNVQm1oMzlQb0FwT3pXLUpqWHJ5UndEOUFmQXdxeEZhbzAyX0pCcERRSEl2a1pmYUZKRW5PYm40cnNyYTJBdm4yUll5MDJnblloQmktdVJPYzBFR2haQzNVRGpJMmVTWEs?oc=5" target="_blank">U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
PR Newswireworld

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxPeXRZUHc3bUIxaVFudV95TXFIaENLNjZoTUZUNXlyMmRub2xUUFY2Q1JKb3gxdlE5SWlBeTFlLVM4aFdhcEZGeVR3dVR6UWFrRE02MzVkbHowbDJ5UXlNQ0pKbmlmeGdNUTZkeFhNelMzeU81YTQ0ZkJONmMtMnB4b1YyMVhfQW9Ra3E4akc0QTNCQUNjRG16RjF3S2xlZ0NXVk5BNUJwRzcwZ19JaGVUV3lrVkVoejlRbnZBMV9tbW5wSEYzMmFaV3dqc3BuazljOFo0ZURRWFNJY1JpRVNfYWJqX1UtdTQzUmpzaW1vOGNOeEVNZzdHMXVsR2VFVzNqQmc?oc=5" target="_blank">FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors
PR Newswiretech

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors

<a href="https://news.google.com/rss/articles/CBMi_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?oc=5" target="_blank">FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Eli Lillyworld

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQWGRTdFVMZ2RNb1JiYkJEYlY5MU94NGxJaU1wRWVBVEd2WnNHSnlVNHJXaVRodDhHNkJmNDYtRFlFaUE0R1BGcm0wT3Z3aVlpeHpwZGRZY0VKZTFSRmJoZmhHQ1NCOUFvcXZzSzZmSHVncFRYWFhXY0FUMEFYYUd1S2d5NjFVUGV5QVFhS2x1eG5SR3dpSHRudmZ1QkF0XzZoTmNNZFF6ZjNnYmZCRWdnVEtYYkJOaUhJNW9xSXNGczBfZw?oc=5" target="_blank">FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity</a>  <font color="#6f6f6f">Eli Lilly</font>

Read Full StoryMore like this
FDA Approves Utebzi for Adults with Complicated Urinary Tract Infections
Pharmaceutical Executivegeneral

FDA Approves Utebzi for Adults with Complicated Urinary Tract Infections

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNX0dRY084Uk1BUldzZnV2Nk9IRm5TQ2dLRWs3cko1NFJXSDVvTndKNWVTX3l6QWdMa1ZmOEZNNUxsbW5LeGpmYmZuSkFOVG1lNUpmOGpLTGg1SDltVzNLTkF2R1VOOTA5ZzV5Umt6MFJGTFZQalJMel9XX2dDaDR2cm93LXpQenA4bldfekhLVWVJRDBORHV1Z3F3?oc=5" target="_blank">FDA Approves Utebzi for Adults with Complicated Urinary Tract Infections</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL
OncLivegeneral

FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOS1FOczhCZFhRcHFadmRpUVdxVGpyZFpYWUE4WEJLS25vVURTZmNSWkxkR0FUeHdQSFRMODlEcUh2RTVpcXAxbFNSX2tqVTZhTXNNVS1XUzBDNndBc0FOazJicU5iZE9hbl9zZlFRR1IzVlMzNmx0QTVSVHNOaFhHV3ZXTG5PclZ6a2I1R1lxclExbG13VEpwZW5n?oc=5" target="_blank">FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA approved LENZ Therapeutics’ VIZZ for the treatment of presbyopia
Optometry Timesgeneral

FDA approved LENZ Therapeutics’ VIZZ for the treatment of presbyopia

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOWHVJOGJZS2tqRmtCVVBFZ1F4MVpQVFlrRVJieVdLVWVSU3NqWkhUMEtCc2M1OV9GeF9Ea3BISEhpY1l4NFpZTDY4ZGV0anlwMmU2czQ4RXp3OWN0S3hteUdpa2NHcjY4V21aNlRxekhUVEF2UVVaNGFIdkxaNl9Vb2hWV2dtRkpIZkU0NU12V1dkTHRCZV8wWE5NVVBScHlYb3lNZGp3?oc=5" target="_blank">FDA approved LENZ Therapeutics’ VIZZ for the treatment of presbyopia</a>  <font color="#6f6f6f">Optometry Times</font>

Read Full StoryMore like this
FDA Approves Imlunestrant for ER+, HER2-Negative, ESR1-Mutated Metastatic Breast Cancer
OncLiveworld

FDA Approves Imlunestrant for ER+, HER2-Negative, ESR1-Mutated Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPRTZmNFdGSUIzcXNMRTVVVHlXLVM3VURRZzNibHRYTGNnNzI5TzF0NDh0TDMwUFgtSUFBQk1zSExCM3FSYnZtZnNHY2x5bXdlUFlpR2dDWnJPWmEzd0VpMW5ld285SmY3MjlpSUhUZGlGdlQyanZTTl94VDgyMFBCV2JZa1o4Q013cHdGakRHMU04eURTcllBWjZadmdsN1RadzdLbmVnTzd4aTBBdm1PeE5JSQ?oc=5" target="_blank">FDA Approves Imlunestrant for ER+, HER2-Negative, ESR1-Mutated Metastatic Breast Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Merck | Hometech

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)

<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxQVUo0NkZpUklwaFhPaDI2dnVabExoNDZOMnAtQU42bkJVcDJUak50dDR4b0dkUTFJWkFNclNlNm43REhGRU4wVDY0S2RQOUQ5UHk2VkNjNWxOZUxxU1ZiTk1yR1dEbjZXcVdFYVQxeEhOTW56czhTUVQ4bnhPdDFwOHl5QnJpMktnNnBWNXZnVWdxUVQ3NnJJdEFiSHZGajFranNndGRoNTFGeGlKTnlRX0VJRWxKSGpQS05KV2s3Z2ZGNFE3S1VYYzd4TENIODRxU05HcEJGUjZfWTBaNTM0TTQ2MFlxcFpOc3RwaFhVcmN4cFdzVlpEaw?oc=5" target="_blank">FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)</a>  <font color="#6f6f6f">Merck | Home</font>

Read Full StoryMore like this
FDA Approves Oral Treatment for CSU
Medscapegeneral

FDA Approves Oral Treatment for CSU

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQOHpPN1RCcnBQWEw2THppMnkyaHE0ekNocjhNNjI5bmtOTW84UV9rWmNienNpSEY0OEs4SFpWLUVYLUsxcXRYazNLX1NkSDdIQmRTLWU2TG4wQVc0cmdYV0hGajZaNXVhRGh2bWF3RWp4OWQwNUhaOVhQTENaWUVxSXp4d09VSlJ0WTc2akZFNjBQdnBMR2JrVm1TMGJqc2FydVo0?oc=5" target="_blank">FDA Approves Oral Treatment for CSU</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
FDA Approves First Drug for MASH
Medscapegeneral

FDA Approves First Drug for MASH

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOV0FoWTMwRXdSdTJMRFgxSDFWUW5KZDRCOWNudXdLSGN4VzZWMDh2WklzLU5vWC1VNXRtbE5sTmVfOGtVT2FWUnJ2bFZqb19vUzJYY2s0MnRJZkt2Y2lXZVFMRHNzYTdWcU5VS09jd1dqaXRxYk1peEJkdkJoYWxWWFoxMWs?oc=5" target="_blank">FDA Approves First Drug for MASH</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
"FDA clears first daily pi" — Live Google News Trends & Headlines